What's new? Log in Free sign up

Sandoz (SDZNY)

Company Profile

Company profile

Ticker

SDZNY

Exchange

Website

CEO

Mr. Richard Saynor

Incorporated

Location

Fiscal year end

SEC CIK

SDZNY stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

Notice of effectiveness

Registration for ADRs (foreign)

Latest ownership filings

No filings

Institutional ownership, Q2 2024

SDZNY institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Sandoz Takes Major Steps Toward Legacy Antitrust Resolution With $275M Settlement And Additional $265M Provision

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesSandoz takes further steps to resolve legacy US generic drug antitrust class action litigationSandoz US has entered into a settlement agreement with

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Sandoz Gains European Commission Approval For Afqlir (aflibercept), Targeting Wider Access Biosimilars In Europe

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to

Sandoz Raised Its 2024 Net Sales Growth Guidance To High-Single Digits In Constant Currency; Maintains Core EBITDA Margin Guidance At ~20%

Sandoz Q3 Sales $2.595B Up From $2.337B YoY

Press releases

From Benzinga Pro

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains

Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.